Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014700 | 1.00 | AHR (0.48) | AHRKCNH2CYP1A2HSD17B10FBP1 | |
| SCHEMBL18821936 | 0.87 | ALDH1A1 (0.41) | KCNH2 | |
| SCHEMBL4774169 | 0.79 | KCNH2 (0.46) | AHRKCNH2CYP1A2HSD17B10FBP1 | |
| SCHEMBL4774178 | 0.79 | KCNH2 (0.46) | AHRKCNH2CYP1A2HSD17B10FBP1 | |
| SCHEMBL3466530 | 0.78 | CYP2C19 (0.43) | GRIK1GRIK2CYP2A6 | |
| SCHEMBL73285 | 0.78 | AHR (0.50) | AHRKCNH2CYP1A2HSD17B10FBP1 | |
| SCHEMBL3466529 | 0.78 | CYP2C19 (0.43) | GRIK1GRIK2CYP2A6 | |
| SCHEMBL73286 | 0.78 | AHR (0.50) | AHRKCNH2CYP1A2HSD17B10FBP1 | |
| SCHEMBL2080531 | 0.76 | AHR (0.48) | AHRKCNH2CYP1A2HSD17B10FBP1 | |
| SCHEMBL11699628 | 0.76 | AHR (0.48) | AHRKCNH2CYP1A2HSD17B10FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024218171-A1 | COMPOUNDS WITH ACTIVITY AGAINST SARS-COV-2 | NATIONAL HELLENIC RESEARCH FOUNDATION (GR) | 2024-10-24 | — | — | WO | disclosed |
| US-9896479-B2 | Functionalized naphthalene fluorophores | Kay M. Brummond (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160046666-A1 | FUNCTIONALIZED NAPHTHALENE FLUOROPHORES | BRUMMOND, KAY M | 2016-02-18 | — | — | US | disclosed |
| US-20160046666-A1 | FUNCTIONALIZED NAPHTHALENE FLUOROPHORES | BRUMMOND, KAY M | 2016-02-18 | — | — | US | disclosed |
| US-9133234-B2 | Functionalized naphthalene fluorophores | Brummond, Kay M. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133234-B2 | Functionalized naphthalene fluorophores | Brummond, Kay M. (US) | 2015-09-15 | — | — | US | disclosed |
| US-8309567-B2 | Spiroindoline derivatives having insecticidal properties | SYNGENTA CROP PROTECTION LLC (US) | 2012-11-13 | — | — | US | disclosed |
| WO-2011137220-A1 | SMALL MOLECULE NEUROPEPTIDE S ANTAGONISTS FOR THE TREATMENT OF ADDICTIVE DISORDERS, MOOD, ANXIETY AND SLEEP DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-11-03 | — | — | WO | disclosed |
| EP-2272858-A2 | HCV inhibitors comprising beta amino acids and their uses | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| EP-1694676-B1 | SPIROINDOLINE DERIVATIVES HAVING INSECTICIDAL PROPERTIES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-08-26 | — | — | EP | disclosed |
| WO-2005058897-A1 | SPIROINDOLINE DERIVATIVES HAVING INSECTICIDAL PROPERTIES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| EP-0234045-B1 | A PYRAZOLE OXIME DERIVATIVE AND ITS PRODUCTION AND USE | NIHON NOHYAKU CO., LTD. (JP) | 1992-09-02 | — | — | EP | disclosed |
| US-4843068-A | INSECTICIDES, MITICIDES, FUNGICIDES | NIHON NOHYAKU CO., LTD. (JP) | 1989-06-27 | — | — | US | disclosed |
| EP-0234045-A2 | A pyrazole oxime derivative and its production and use | NIHON NOHYAKU CO., LTD. (JP) | 1987-09-02 | — | — | EP | disclosed |
| US-4308273-A | 1,6-Naphthyridine derivatives, and antidinic and cerebral circulation improver containing such derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1981-12-29 | — | — | US | disclosed |
| EP-0000154-B1 | NEW BENZ(F)ISOINDOLINES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | SANDOZ AG (CH) | 1981-07-29 | — | — | EP | disclosed |
| US-4171369-A | ANALGESICS, ANTIDEPRESSANTS | SANDOZ LTD. (CH) | 1979-10-16 | — | — | US | disclosed |
| US-4164583-A | SEDATIVES, TRANQUILIZERS | SANDOZ LTD. (CH) | 1979-08-14 | — | — | US | disclosed |
| EP-0000154-A1 | New benz(f)isoindolines, their preparation and medicaments containing them | SANDOZ AG (CH) | 1979-01-10 | — | — | EP | disclosed |
| US-3956374-A | Aryl-oxo-heptenoic acids | MERCK & CO., INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046666-A1 | FUNCTIONALIZED NAPHTHALENE FLUOROPHORES | NCL, SNW1, NEK1 | AHR 136/4885KCNH2 1971/4885CYP1A2 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.